Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690207 · ClinicalTrials.gov registry record · Phase 3
Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.
A Phase 3 study of Herpes Zoster, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,687
- Enrollment target
- 20
- Study locations
NCT02690207: Completed Phase 3 study of Herpes Zoster, sponsored by GlaxoSmithKline.
NCT02690207 is a Phase 3 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 8,687 participants, above the 1,631-participant average among 16 other Herpes Zoster trials with a reported enrollment target (433% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02690207, a Phase 3 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,687 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).
Primary Outcome
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related=AE assessed by the investigator as related to the vaccination.
Conditions Studied
Interventions
- BIOLOGICAL Herpes Zoster Vaccine GSK1437173A
Study Locations (20)
Arizona
- GSK Investigational Site - Mesa
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Tucson
Florida
- GSK Investigational Site - Clearwater
- GSK Investigational Site - DeLand
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - Jacksonville
- GSK Investigational Site - West Palm Beach
Maryland
- GSK Investigational Site - Columbia
- GSK Investigational Site - Elkridge
North Carolina
- GSK Investigational Site - Cary
- GSK Investigational Site - Charlotte
California
- GSK Investigational Site - Spring Valley
Idaho
- GSK Investigational Site - Meridian
Kansas
- GSK Investigational Site - Wichita
Missouri
- GSK Investigational Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,687 participants |
| Start Date | 2016-03-16 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 3 |
What the finished NCT02690207 record still lists
NCT02690207 is an interventional study that assigns participants to a tested intervention. Its 8,687 participants enrollment target places it among the larger protocols in the corpus, above the 1,631-participant average among 16 other Herpes Zoster trials with a reported enrollment target (433% higher).
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 1 intervention - of which Herpes Zoster Vaccine GSK1437173A is the first listed.
NCT02690207 names 20 study sites across 10 states, led by Arizona, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT02690207 about?
NCT02690207 is a clinical study titled "Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.". The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects \>= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOS...
What is the current status of trial NCT02690207?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,687 participants. The study started on 2016-03-16. Estimated completion is 2019-03-15.
What conditions does trial NCT02690207 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT02690207?
The interventions under investigation include: Herpes Zoster Vaccine GSK1437173A (BIOLOGICAL).
Who is sponsoring clinical trial NCT02690207?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02690207 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02690207's enrollment target sits among peer trials
8,687 2nd of 16 the highest of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
ACTIVE NOT RECRUITING · Phase 3
-
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
COMPLETED · Phase 3
-
Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
COMPLETED · Phase 3
-
Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
COMPLETED · Phase 3
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI